Marwan Sabbagh, MD, shares strategies for the differential diagnosis of dementia, along with implications of new developments like the advent of blood tests for the presence of brain amyloid plaques.
A genetic variant of the tumor necrosis factor receptor 2 pathway is associated with modulation of indicators of Alzheimer’s disease severity and slower functional decline. These cohort study findings hold promise for development of targeted therapies.
Most therapies in development for Alzheimer’s are focused on changing disease biology, with targets ranging from amyloid pathology to inflammation. A leader of our clinical trials program shares an update on drug development and diagnostics.
This risk gene increases the odds that initial symptoms will involve memory in patients with Alzheimer’s but not in those with Lewy body disease. So finds a large cohort study with implications for targeted therapeutics.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A screening blood test could accelerate drug development and enable earlier, more effective intervention. We offer an overview of promising efforts in pursuit of a reliable blood-based biomarker.